Heron Therapeutics Inc. (NASDAQ:HRTX) has been assigned an average recommendation of “Buy” from the ten analysts that are currently covering the stock. One research analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $40.86.

Several analysts have commented on HRTX shares. JMP Securities reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, November 9th. Aegis started coverage on shares of Heron Therapeutics in a research note on Wednesday, October 26th. They issued a “buy” rating and a $41.00 price target on the stock. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Leerink Swann restated a “buy” rating and set a $33.00 target price on shares of Heron Therapeutics in a research report on Sunday, October 2nd. Finally, Cantor Fitzgerald restated a “buy” rating and set a $41.00 target price on shares of Heron Therapeutics in a research report on Wednesday, August 3rd.

Heron Therapeutics (NASDAQ:HRTX) opened at 19.00 on Monday. Heron Therapeutics has a one year low of $13.95 and a one year high of $31.32. The firm’s 50-day moving average price is $16.53 and its 200 day moving average price is $18.09.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.07. On average, analysts anticipate that Heron Therapeutics will post ($4.50) EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of HRTX. JPMorgan Chase & Co. raised its stake in Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock worth $6,622,000 after buying an additional 19,737 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in shares of Heron Therapeutics during the first quarter worth approximately $734,000. Panagora Asset Management Inc. increased its position in shares of Heron Therapeutics by 90.3% in the first quarter. Panagora Asset Management Inc. now owns 245,392 shares of the biotechnology company’s stock worth $4,660,000 after buying an additional 116,461 shares in the last quarter. Cormorant Asset Management LLC increased its position in shares of Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock worth $33,233,000 after buying an additional 64,281 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Heron Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 147,986 shares of the biotechnology company’s stock worth $2,672,000 after buying an additional 4,579 shares in the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.